期刊文献+

4种喹诺酮类药物治疗呼吸系统感染成本-效果分析

Cost-Effectiveness Analysis of Four Kinds of Quinolone Drug in Treatment of Respiratory System Infection
下载PDF
导出
摘要 目的比较4种喹诺酮类药物治疗呼吸系统感染的成本-效果。方法采用回顾性研究方法,选择120例呼吸系统感染患者,随机分为A(门冬氨酸洛美沙星)、B(甲磺酸帕珠沙星)、C(盐酸左氧氟沙星)、D(氟罗沙星)4组,进行成本-效果分析。结果 A,B,C,D组的成本分别为872.48,716.80,512.40,562.80元,临床有效率分别为93.33%,90.00%,86.67%,83.33%,成本-效果比分别为9.35,7.96,5.91,6.75。以D组为参照,A,B,C组的增量成本-效果比分别是30.97,23.09,-15.09。结论 C组治疗方案(左氧氟沙星)较经济合理。 Objective To analyze the expenses and effect of four kinds of quinolone drug in treatment of respiratory system infection. Methods The retrospective study was performed. A total of 120 patients with respiratory system infection receiving chemotherapy were randomly assigned to lomefloxacin aspartate (group A),pazufloxacin mesylate (group B),levofloxacin hydrochloride (group C),or fleroxacin ( group D) ,respectively. The therapeutic effects were monitored and the cost-effectiveness analyses were conducted on the four groups. Results The costs of four groups were 872. 48,716. 80,512. 40,562. 80 yuan,respectively. The effective rates of four groups were 93. 33% , 90. 00%,86. 67% and 83. 33%,respectively. The cost-effectiveness ratios of four groups were 9. 35,7. 96,5. 91 and 6. 75,respectively. Compared with group D,incremental cost-effectiveness ratios of group A,B,C were 30. 97,23. 09,-15. 09,respectively. Conclusion Group C was the most reasonable option among the four groups.
出处 《中国药业》 CAS 2010年第16期50-52,共3页 China Pharmaceuticals
关键词 喹诺酮类药物 呼吸系统感染 成本-效果分析 quinolone drugs respiratory system infection cost-effectiveness analysis
  • 相关文献

参考文献5

二级参考文献17

  • 1张钧,郭震洲,王立强,任守英.药物经济学概述及在我国运用的几点设想[J].中国药房,1993,4(5):11-13. 被引量:94
  • 2阎依群.利用药品的成本效益分析减少药品消耗[J].中国药房,1994,5(3):6-7. 被引量:5
  • 3张钧.药物经济学概论[J].药学实践杂志,1995,13(1):3-6. 被引量:79
  • 4宋秉鹏,丁玉峰.药物经济学概述[J].药物流行病学杂志,1996,5(3):179-183. 被引量:306
  • 5[8]Ji H,Leung M,Zhang Y,et al.Differential structural requirements for specific binding of hon-pep-tide and peptide antagonists to the AT1 angiotensin receptor and identification of amino acidresidves.that determine bringing of the antiby pertensive drug losartan[J].J Biol Clem,1994,26(9):533.
  • 6[9]Timmermans PB.Pharmacological properties of angiotensin-receptor antagonists[J].Can J Cardiol,1999,15(7):26.
  • 7[10]Kloner RA,Weinberger M,Pool JL,et al.Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemil hypertension,comparison of candesartan and amlodipine for safety,tolerability and efficacy (CASTLE) study in vestigations[J].Am J Cardiol,2001,87(6):727.
  • 8吴永佩 张钧.医院管理学-药事管理分册[M].北京:人民卫生出版社,2003..
  • 9国家药品监督管理局执业药师资格认证中心.药学综合知识与技能[M].北京:中国中医药出版社,..
  • 10陈洁.药物经济学评估对医药市场的影响[C]..首届全国药学服务与研究学术会议论文集[C].,2004-10..

共引文献940

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部